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background:  Alirocumab added to statin therapy has shown robust reductions in low-density lipoprotein cholesterol (LDL-C) and can 
also reduce it to very low levels. Consequences of very low LDL-C levels are not well understood. Therefore, AE rates were examined in 
patients (pts) who achieved 2 consecutive calculated LDL-C <25 or <15 mg/dL on alirocumab (ALI).
Methods:  14 trials were analyzed; 4 Phase 2 (8-12 weeks and completed) and 10 from the ODYSSEY program (6-24 months with double-
blind safety assessment still ongoing in some). The pooled group comprises 5234 pts (3340 ALI and 1894 control). TEAEs were analyzed. 
LONG TERM (LTT), in which 2338 pts received ALI 150 mg or control every 2 weeks for up to 78 weeks, included laboratory tests for 
parameters that might be related to very low LDL-C.
Results:  In the pooled ALI group, 796 (23.8%) pts, including 562 (36.3%) pts from LTT achieved LDL-C <25 mg/dL on ≥2 consecutive 
visits, and 288 (8.6%) from the pooled ALI group, including 223 (14.3%) from LTT, achieved LDL-C <15 mg/dL. TEAEs were generally 
similar across all groups. There were no cases of hemolytic anemia. In LTT, no clinically meaningful effect was observed in changes to 
cortisol levels or fat soluble vitamins.
conclusion:  In one of the largest evaluations of patients with pharmacologically-induced LDL-C <25 or <15 mg/dL, no safety signals were 
observed. Evaluations of the ongoing cardiovascular outcomes trial will extend these findings.
TABLE Select TEAEs ≥2% incidence in any group by primary system organ class and preferred term in the pooled group† and ODYSSEY LONG TERM
Primary system organ class, % (n)
Preferred term, % (n)
Pooled control
(N=1894)†
Pooled alirocumab
(N=3340)†
Pooled alirocumab 
2 LDL-C <25 
mg/dL
(N=796)†
Pooled alirocumab 2 
LDL-C <15 mg/dL
(N=288)†
LONG TERM alirocumab 
2 LDL-C <25 mg/dL
(N=562)
Infections and infestations 36.3 (687) 38.5 (1286) 34.0 (271) 35.4 (102) 39.0 (219)
Nasopharyngitis 9.3 (176) 9.8 (326) 8.3 (66) 10.1 (29) 10.0 (56)
Upper respiratory tract infection 6.7 (126) 6.1 (203) 4.5 (36) 5.2 (15) 5.7 (32)
Urinary tract infection 4.1 (77) 4.1 (137) 4.6 (37) 4.9 (14) 5.5 (31)
Influenza 3.9 (73) 5.2 (173) 3.6 (29) 4.2 (12) 4.1 (23)
Bronchitis 3.3 (63) 3.8 (126) 4.4 (35) 3.1 (9) 5.2 (29)
Sinusitis 2.7 (51) 2.6 (87) 2.6 (21) 3.1 (9) 3.0 (17)
Lower respiratory tract infection 1.4 (26) 1.6 (53) 2.0 (16) 2.1 (6) 2.8 (16)
Gastroenteritis 2.3 (43) 1.9 (62) 0.6 (5) 1.0 (3) 0.7 (4)
Cellulitis 0.6 (11) 0.9 (30) 1.1 (9) 0 (0) 1.6 (9)
Rhinitis 1.2 (22) 0.9 (29) 0.9 (7) 0.7 (2) 1.2 (7)
Musculoskeletal and connective 
tissue disorders 25.2 (478) 24.2 (808) 21.1 (168) 20.1 (58) 22.6 (127)
Back pain 4.3 (82) 4.0 (133) 4.3 (34) 4.2 (12) 5.0 (28)
Arthralgia 5.0 (95) 4.0 (134) 3.1 (25) 2.1 (6) 3.2 (18)
Myalgia 4.8 (91) 4.9 (162) 3.1 (25) 3.8 (11) 3.0 (17)
Muscle spasms 2.4 (45) 2.8 (94) 2.5 (20) 3.5 (10) 2.8 (16)
Pain in extremity 3.4 (64) 2.4 (81) 2.1 (17) 1.4 (4) 2.1 (12)
Osteoarthritis 2.2 (42) 2.1 (69) 1.8 (14) 1.0 (3) 2.1 (12)
Musculoskeletal pain 1.4 (27) 1.9 (65) 1.0 (8) 1.0 (3) 1.4 (8)
Gastrointestinal disorders 16.8 (318) 17.0 (567) 12.7 (101) 10.1 (29) 13.7 (77)
Diarrhea 3.9 (74) 4.3 (142) 3.0 (24) 1.4 (4) 3.9 (22)
Nausea 2.5 (47) 2.2 (74) 0.9 (7) 1.0 (3) 0.9 (5)
Constipation 1.4 (27) 1.7 (58) 1.1 (9) 1.4 (4) 1.6 (9)
General disorders and administration 
site conditions 14.9 (282) 15.1 (504) 10.2 (81) 6.9 (20) 11.0 (62)
Injection site reaction 3.9 (73) 5.7 (191) 3.0 (24) 3.5 (10) 3.6 (20)
Fatigue 2.5 (48) 2.8 (93) 2.6 (21) 2.4 (7) 3.0 (17)
Non-cardiac chest pain 1.8 (35) 1.6 (54) 1.8 (14) 0.3 (1) 2.0 (11)
Nervous system disorders 14.9 (283) 14.9 (497) 10.3 (82) 9.0 (26) 11.2 (63)
Dizziness 3.6 (69) 3.0 (100) 1.8 (14) 1.4 (4) 1.4 (8)
Headache 4.6 (87) 4.6 (153) 1.8 (14) 1.4 (4) 1.8 (10)
Metabolism and nutrition disorders 6.3 (120) 6.9 (232) 7.0 (56) 7.3 (21) 8.0 (45)
Type 2 diabetes mellitus 0.7 (14) 1.1 (36) 1.8 (14) 1.4 (4) 2.5 (14)
Diabetes mellitus 1.3 (24) 1.2 (39) 1.5 (12) 2.4 (7) 1.4 (8)
Eye disorders 3.7 (71) 4.6 (152) 5.3 (42) 6.9 (20) 6.4 (36)
Cataract 0.9 (17) 0.8 (26) 1.5 (12) 2.4 (7) 1.8 (10)
Neoplasms benign, malignant and 
unspecified (incl. cysts and polyps) 2.5 (48) 2.5 (85) 2.8 (22) 2.4 (7) 3.0 (17)
Additional parameters possibly related to low LDL-C, as measured in LTT 
Laboratory parameter, % (n/N1) Placebo(N=788)
Alirocumab
(N=1550)
Cortisol
<LLN 20.1 (154/767) 19.6 (295/1506)
<LLN and ACTH >ULN 0.6 (1/154) 0.7 (2/295)
<LLN and ACTH >ULN and normal ACTH stimulation test 100 (1/1) 50.0 (1/2)
<LLN and ACTH >ULN and abnormal ACTH stimulation test‡ 0/1 50.0 (1/2)
Fat soluble vitamins
Vitamin E <LLN regardless of baseline status 0.1 (1/738) 2.1 (31/1461)
Vitamin A <LLN regardless of baseline status 0.3 (2/762) 0.1 (2/1494)
Vitamin D <LLN regardless of baseline status 86.8 (659/759) 85.1 (1270/1493)
Vitamin K <LLN regardless of baseline status 5.5 (42/762) 8.4 (125/1496)
ACTH, adrenocorticotropic hormone; AE, adverse event; LLN, lower limit of normal; TEAE, treatment-emergent adverse event; ULN, upper limit of normal
†Phase 3 (ODYSSEY LONG TERM, FH I, FH II, HIGH FH, COMBO I, COMBO II, MONO, OPTIONS I, OPTIONS II, ALTERNATIVE; NCT01507831, 01623115, 
01709500, 01617655, 01644175, 01644188, 01644474, 01730040, 01730053, 01709513) ; Phase 2 (DFI11565, DFI11566, CL-1003, DFI12361; NCT01288443, 
01288469, 01266876, 01812707)
‡Abnormal ACTH stimulation test is defined as cortisol value <18 µg/dL (<497 nmol/L) at both 30 and 60 minutes after ACTH administration
